Parkinson's Disease In The Crossfire 2008


CME Information

Earn Hours Of AMA PRA Category 1 Credit™

Focus on Neuroprotection 2008

1 Hour

Designation Statement
Ciné-Med, Inc. designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Target Audience
This activity is intended for neurologists and other medical professionals with a specific interest in the management of Parkinson's Disease.

Release Date: July 1, 2008
Expiration Date: July 1, 2010


Learning Objectives:
At the conclusion of this continuing medical education activity, participants should be able to:

  • Discuss current concepts related to the etiology and pathogenesis of Parkinson's Disease
  • Identify candidate targets and agents for putative neuroprotective  drugs
  • Identify the positive and negative clinical trials that  have been performed to date
  • Identify obstacles to development of a neuroprotective therapy

Focus on Treatment 2008

1 Hour

Designation Statement
Ciné-Med, Inc. designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Target Audience
This activity is intended for neurologists and other medical professionals with a specific interest in the management of Parkinson's Disease.

Release Date: April 1, 2008
Expiration Date: April 1, 2010


Learning Objectives:
At the conclusion of this continuing medical education activity, participants should be able to:

  • Discuss the importance of early diagnosis in terms of effective treatment
  • Differentiate the treatment options available for initial treatment of Parkinson's Disease
  • Discuss the management of motor complications and identify different treatment modalities
  • Identify non-motor features of Parkinson's Disease and their significance in Parkinson's Disease

Focus on Treatment 2007

1 hour 8 minutes

Designation Statement
Ciné-Med, Inc. designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Target Audience
This activity is intended for neurologists and other medical professionals with a specific interest in the management of Parkinson's Disease.

Release Date: July 15, 2007
Expiration Date: July 15, 2009


Learning Objectives:
At the conclusion of this continuing medical education activity, participants should be able to:

  • Discuss the reasons to consider early treatment for Parkinson's Disease and what agents are appropriate for initial therapy
  • Discuss options for medical management of advanced Parkinson's Disease
  • Differentiate the surgical treatment options available for advanced motor complications
  • Discuss the pros and cons of infusion therapy
  • Identify some of the therapies being explored for future PD treatment

Focus on Neuroprotection 2007

45 minutes

Designation Statement
Ciné-Med, Inc. designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Target Audience
This activity is intended for neurologists and other medical professionals with a specific interest in the management of Parkinson's Disease.

Release Date: October 1, 2007
Expiration Date: October 1, 2009


Learning Objectives:
At the conclusion of this continuing medical education activity, participants should be able to:

  • Describe the non-dopaminergic features of Parkinson's Disease
  • Identify the most common disabling non-dopaminergic symptoms
  • Identify the major unmet medical need in Parkinson's Disease
  • Differentiate putative neuroprotective agents that failed in clinical trials from those that met the outcome measure
  • Discuss the prospects for neuroprotection in Parkinson's Disease

In The Crossfire: 2006

2 hours

Designation Statement
Ciné-Med, Inc. designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Target Audience
This activity is intended for neurologists and other medical professionals with a specific interest in the management of Parkinson's Disease.

Release Date: July 15, 2006
Expiration Date: July 15, 2008


Learning Objectives:
At the conclusion of this continuing medical education activity, participants should be able to:

  • Define the diagnostic criteria for Parkinson's Disease
  • Describe the importance of early diagnosis in terms of effective treatment
  • Differentiate the treatment options available for both early and advanced Parkinson's Disease
  • Discuss neuroprotection and the value of new agents that potentially confer this therapeutic property

How to get CME credit
To receive credit, participants must view the webcast or DVD, register on this site, and successfully complete the post-test and evaluation (successful passing grade ≥70%). Certificates can be printed on line.

Accreditation
These educational activities have been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Ciné-Med, Inc. and Astute Technology. Ciné-Med, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

Disclosure statement
Ciné-Med, Inc. in accordance with the ACCME's Standards for Commercial Support, requires individuals with control over content to disclose to learners any relevant financial relationships(s). Faculty disclosures can be found on the Faculty page.

These continuing medical education activities are jointly sponsored by Ciné-Med, Inc. and Astute Technology.

Commercial Support
These activities are supported by an educational grant from Teva Neuroscience.